Glivec News

Pharmaceutical companies commonly used legal argument, as opposed to demonstrating proof of therapeutic efficacy, to overcome anti-evergreening objections

Senior advocate Prathiba M. Singh, a leading intellectual property (IP) litigator, on why India is emerging as a jurisdiction with a distinctive patent regime

Reliance Life Sciences introduces six anti-cancer drug brands in India, including a generic version of Glivec

Novartis says India needs to have fast track courts to deal with IPR disputes

Increasing evidence over the last decade has pointed to the patent system being a bottleneck for research itself and access to affordable medicines

While interest groups spin the outcome into a pricing issue, many important details about its implications are getting lost

India’s top court misses an opportunity to answer this question decisively with an all-too-specific judgement in the contentious Glivec case

Incremental improvements of existing products to secure patents are a menace to innovation

India must quickly tighten its position on patenting genes and explicitly defining incremental innovation

Just because companies make drugs, should they aspire to less profits than a firm that makes trendy electronic goods?